Patient Centricity in Pharma & Medical Affairs

Growing consumerism. Regulatory shifts. Recognition of diverse patient needs. Advances in data and analytics. These forces drive patient centricity in pharma. In medical affairs, true patient centricity medical affairs means moving beyond traditional HCP engagement to capture real-world patient experiences. For more info: https://www.zs.com/insights/pa....tient-centricity-med

Bio pharma R&D category & biotech commercialization strategy

For bio pharma r&d category strategy, shifting from science‑first to patients‑first is crucial. Data challenges assumptions (e.g., redefining target physicians). Market access is non‑negotiable; without reimbursement readiness, prescriptions fail. For more info: https://www.zs.com/insights/bi....opharma-commercializ

Medical Affairs Platform for Evidence & Strategy

Medical affairs and evidence generation now function as a strategic powerhouse. Experts help teams lead by scaling science, insights, and engagement throughout the product lifecycle. By leveraging an intelligent medical affairs platform, organizations can shape strategy, generate critical evidence, and execute with confidence to improve patient outcomes from research to bedside. For more info: https://www.zs.com/capabilitie....s/research-and-devel

B2B sales digital transformation and go to market success

Scarcely a week goes by without headlines on digital shifts. While most B2B organizations understand the imperative to use technology and data for growth, many struggle to realize significant gains from their investments. The core challenge is an inability to integrate people, systems, and strategies into a unified ecosystem that delivers personalized omnichannel experiences. For more info: https://www.zs.com/insights/ho....w-digitalization-tra

Boosting pharma R&D productivity with strategic ROI

As the industry navigates patent expirations and legislation like the Inflation Reduction Act, improving pharma R&D productivity is key to offsetting challenges. After decades of increasing costs, recent reductions in cycle times are promising. For more info: https://www.zs.com/insights/ph....arma-randd-productiv